Advanced Cancer Clinical Trial
Official title:
Phase I Study of Paclitaxel Administered by Hepatic Artery Infusion to Patients With Advanced Cancer and Dominant Liver Involvement
The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver. Researchers also want to collect descriptive information on any effects the drug may have on tumor tissue.
Paclitaxel is designed to work by blocking the mechanisms of cell division in cancer cells,
causing them to die.
Before you can start on this study, you will have what are called "screening tests." These
tests will help the doctor decide if you are eligible to take part in this study. You will
have a complete medical history and physical exam, including measurement of height, weight,
and vital signs (blood pressure, temperature, breathing rate, and heart rate). You will have
a neurological evaluation evaluating your strength and nerve function. You will be asked to
report how a pinprick or a thin brush feel when applied to your skin. About 2 tablespoons of
blood and some urine samples will be collected for routine tests. Women who are able to have
children must have a negative urine pregnancy test.
If you are eligible to take part in this study, you will begin taking study drugs in cycles
of 28 days. You will be hospitalized to receive your chemotherapy. The night of the hospital
admission, you will receive fluids (normal saline) in your veins to help decrease the risk
of kidney side effects from the chemotherapy. The morning after your admission to the
hospital, you will be taken to the interventional radiology suite, and a catheter (a thin
plastic tube) will be placed in your groin area and advanced to the liver. You must be on
bedrest the entire time that the catheter is in place. After the procedure, you will go to
Nuclear Medicine, and a test called "flow study" will be carried out to confirm the right
position of the catheter. After your return to the room, the nurses will start the
chemotherapy. You will receive paclitaxel nonstop over 24 hours through the catheter (a thin
plastic tube) into the artery that carries blood to your liver. You will repeat this
procedure once every month.
The catheter will be carefully taped so that it can not move and to prevent it from coming
out while you are receiving chemotherapy. You will be asked to lie flat on your back while
the treatment takes place. In some cases, the catheter will be removed immediately after
your chemotherapy infusions is complete. In some cases, the catheter will remain in longer.
You will be on bedrest until the catheter is removed. When the catheter is pulled, pressure
will be applied to the groin for 15 minutes. The catheter will be removed by someone
experienced in the procedure. The catheter will be placed and removed for each cycle of
chemotherapy. Blood (about 2 teaspoons) will be drawn for blood counts and liver function
tests, before each dose, to be sure researchers are safely giving you the paclitaxel.
You will be seen by a doctor or advanced practitioner every day while you are in the
hospital. You will be hospitalized for about 3-5 days until recovery from all immediate
chemotherapy-related side effects. The charges of your hospitalization will be billed to you
or your insurance carrier.
You will continue to receive the chemotherapy once every 28 days, unless the disease gets
worse or intolerable side effects occur. Every 2 months and at the end of your participation
in this study, you will have scans to see if your tumors are growing or shrinking and blood
work (about 3 teaspoons) will be performed for safety tests. These tests can be performed at
your doctor's office and the results faxed to the study doctor at M. D. Anderson.
In addition, you will be asked to call the research nurse in charge of this study at
713-745-1042 to report on your health status every week for 30 days after the last dose of
the drug or until you start a new course of therapy.
This is an investigational study. The chemotherapy you will be given is FDA approved. The
cost of being on these medications will be billed to you or your insurance company. About 59
patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
| Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
| Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |